In vivo modeling of cancer is a critical step in testing novel therapeutic strategies to advance patient care. Here we describe how to develop a humanized patient-derived xenograft (PDX) model of ovarian cancer that uses orthotopically transplanted patient ovarian tumors with autologous transfer of expanded tumor infiltrating T cells (TILs) as a model that can be utilized to test immunomodulating therapeutics in vivo.
Keywords: Immune checkpoint blockade; Immunotherapy; In vivo modeling; Patient-derived xenograft; T-cell expansion; Tumor infiltrating lymphocytes.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.